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Aims and objectives: Multidrug-resistant tuberculosis (MDR-TB) has become a major public
health problem worldwide, which lays a heavy burden on low- and middle-income coun-
tries. Compared with newly diagnosed tuberculosis (TB) patients, patients with a history
of anti-TB treatment have increased mortality and a higher prevalence of drug resistance.
However, these patients are neglected by both global and national TB control programs and
have met barriers to access to medical care for potential drug resistance. This study aims to
understand the drug-resistance status of patients with previous treatment history and
to determine the factors associated with the accessibility of bacteriological-based TB
diagnosis.
Methods: A cross-sectional study was conducted in 8 county/district TB clinics in three
provinces (Jiangsu, Shandong and Sichuan) of China, where a global fund-supported
MDR-TB control project had been initiated. TB patients who had at least one previous treat-
ment episode were interviewed using a structured questionnaire. Information on demo-
graphics, socioeconomic status of patients, and their experiences on seeking TB
diagnosis and treatment were collected.
Results: A total of 196 smear-positive TB patients were recruited, of which 78% (153/196)
were male and the average age of these patients was 57 years old. About 70% (137/196) of
the subjects were farmers, and 63% (121/195) had less than 6 years’ education. Among
these patients, 120 cases (61.22%) received culture-based TB diagnosis in this treatment
episode, while patients from Jiangsu province (versus Shandong/Sichuan aOR: 8.10/36.42,
95% CI: 2.70–24.25/12.20–108.66) and patients with a higher annual income per capita
(aOR: 3.35, 95% CI: 1.26–8.92) were found to be more likely to reach culture tests after adjust-
ing for gender and age. MTB complex and non-tuberculosis mycobacteria (NTM) strains
were isolated from 92 and 10 patients, respectively, and the remaining 18 patients were
negative to bacteria culture. Drug sensitivity testing (DST) for first-line anti-TB drugs,
and kanamycin and ofloxacin, was completed for the 92 MTB isolates. The total proportion
of drug-resistant tuberculosis was 52.48% (47/92), while the prevalence for resistance to a
single drug, multidrug-resistant and other combinations of drug resistance were 16.30%
(95% CI: 9.78–23.91%), 30.43% (95% CI: 21.74–40.22%), and 4.35% (95% CI: 1.09–8.70%),
respectively. Resistance to isoniazid, rifampicin, streptomycin, ethambutol, kanamycin
and ofloxacin was 36.96%, 35.87%, 23.91%, 10.87%, 4.35% and 6.52%, respectively.8, No. 138
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drug-resistant tuberculosis in China. The poor accessibility of bacteriological-based
diagnosis may aggravate the difficulty of detection and control for drug-resistant
TB patients. The next step of the anti-TB strategy should be focused on how to make
bacteriological-based diagnosis cheaper, safer and more maneuverable and on how to
assure the DST-guided treatment for these high-risk TB patients.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.
